-
First vaccine to protect against Ebola
First vaccine to protect against Ebola
-
First vaccine to protect against Ebola
First vaccine to protect against Ebola
EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation for the first vaccine for active immunisation of people at risk of infection with Ebola virus.
-
CHMP highlights: October 2019
CHMP highlights: October 2019
-
CHMP highlights: October 2019
CHMP highlights: October 2019
EMA’s human medicines committee (CHMP) recommended seven medicines for approval, including the first vaccine against Ebola, at its 14-17 October meeting.
-
Update on nitrosamine impurities
Update on nitrosamine impurities
-
Update on nitrosamine impurities
Update on nitrosamine impurities
EMA has updated the Q&A document for marketing authorisation holders who are currently reviewing their medicines for the possible presence of nitrosamines and testing products at risk. The document lists potential sources of nitrosamine contamination that have been identified to date.
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
-
Updated guidance for industry on preparing for Brexit
Updated guidance for industry on preparing for Brexit
EMA and the European Commission provide additional information on exemptions for batch testing to help pharmaceutical companies prepare for the UK’s withdrawal from the EU.
